64 Sydney Street
About Cardurion PharmaceuticalsCardurion is a recently launched, Boston-based cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. In July, 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced the creation of a new preclinical partnership to develop novel, next-generation therapeutics for the treatment of heart failure and cardiovascular diseases. The partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists in an entrepreneurial setting and enables the Discovery programs of Cardurion.
Cardurion is led by two distinguished physician-scientists with extensive experience in cardiovascular science, medicine and drug development: Daniel Bloomfield, M.D. chief executive officer and Michael Mendelsohn, M.D. founder and executive board chairman.
Founder & Chairman: Michael E. Mendelsohn, M.D.
CEO: Daniel M. Bloomfield, M.D.
5 articles with Cardurion Pharmaceuticals
Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure
Cardurion Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733
Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.
Cardurion Pharmaceuticals is pleased to share the members of its Scientific and Clinical Advisory Boards.
Company expanding pipeline of novel treatments for cardiovascular disease